Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasacort AQ in children 2-5 with perennial allergic rhinitis
NCT00132925Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2003
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing Nasacort AQ Arm with Placebo Arm (2 arms). Primary endpoints: Total Nasal Symptom Score (instantaneous) at 4 weeks and Global evaluation of efficacy. Started Nov 2003; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00132925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132925.